Free Trial

RayzeBio (RYZB) Stock Forecast & Price Target

Notice: This company has been marked as potentially delisted and may not be actively trading.

RayzeBio - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 5 Analyst Ratings

Consensus Price Target

$31.33
-49.86% Downside
High Forecast$35.00
Average Forecast$31.33
Low Forecast$29.00
TypeCurrent Forecast
6/6/23 to 6/5/24
1 Month Ago
5/7/23 to 5/6/24
3 Months Ago
3/8/23 to 3/7/24
1 Year Ago
6/6/22 to 6/6/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
N/A
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$31.33$31.33$31.33N/A
Forecasted Upside-49.86% Downside48.99% Upside48.99% UpsideN/A
Get RayzeBio Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RYZB and its competitors with MarketBeat's FREE daily newsletter.

RYZB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RYZB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

RayzeBio Stock vs. The Competition

TypeRayzeBioMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.69
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside-49.86% Downside820.71% Upside10.92% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/26/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hsieh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
10/11/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
10/10/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$29.00+37.90%
10/10/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$30.00+42.65%
10/10/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$35.00+66.43%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:09 AM ET.

RYZB Frequently Asked Questions

What is RayzeBio's stock forecast and purchase recommendation?

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for RayzeBio is $31.33, with a high forecast of $35.00 and a low forecast of $29.00. The consensus rating for RayzeBio stock is Moderate Buy based on the current 1 hold rating and 4 buy ratings for RYZB. Learn more on RYZB's analyst rating history.

Do Wall Street analysts like RayzeBio more than its competitors?

Analysts like RayzeBio more than other "medical" companies. The consensus rating score for RayzeBio is 2.80 while the average consensus rating score for "medical" companies is 2.69. Learn more on how RYZB compares to other companies.

Does RayzeBio's stock price have much upside?

According to analysts, RayzeBio's stock has a predicted upside of 48.99% based on their 12-month stock forecasts.


Stock Forecasts and Research Tools

Related Companies:
This page (NASDAQ:RYZB) was last updated on 6/5/2024 by MarketBeat.com Staff

From Our Partners